Mycophenolic acid (Synonyms: 霉酚酸; Mycophenolate)

目录号: HY-B0421 纯度: 99.94%: Data Sheet SDS COA 产品使用指南
FAQs
技术支持

Mycophenolic acid 是一种有效的非竞争性肌苷单磷酸脱氢酶 (IMPDH) 抑制剂，EC₅₀ 为 0.24 μM。Mycophenolic acid 对多种 RNA 病毒具有抗病毒作用，包括流感 (influenza)。Mycophenolic acid 是一种免疫抑制剂。具有抗血管生成和抗肿瘤作用。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Mycophenolic acid Chemical Structure

CAS No. : 24280-93-1

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥605	In-stock
100 mg	￥550	In-stock
500 mg	￥1100	In-stock
1 g	￥1505	In-stock
5 g	￥3010	In-stock
10 g		询价
50 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Mycophenolic acid:

MCE 顾客使用本产品发表的 11 篇科研文献

Mycophenolic acid 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Antibiotic 亚型特异性产品:

查看所有亚型

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

生物活性
纯度 & 产品资料
参考文献

生物活性

Mycophenolic acid is a potent uncompetitive inosine monophosphate dehydrogenase (IMPDH) inhibitor with an EC₅₀ of 0.24 µM. Mycophenolic acid demonstrates antiviral effects against a wide range of RNA viruses including influenza. Mycophenolic acid is an immunosuppressive agent. Antiangiogenic and antitumor effects^[1]^[2].

IC₅₀ & Target

Microbial Metabolite

Human Endogenous Metabolite

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.4 μM Compound: 1	In vitro antitumor activity against A549 human NSCLC lung carcinoma cells In vitro antitumor activity against A549 human NSCLC lung carcinoma cells	10.1016/0960-894X(95)00130-L
A549	IC₅₀	1.21 μM Compound: MPA; 1	Cytotoxicity against human A549 cells assessed as growth inhibition measured by SRB assay Cytotoxicity against human A549 cells assessed as growth inhibition measured by SRB assay	[PMID: 34044119]
BHK-21	CC₅₀	3.55 μM Compound: 61	cytotoxicity against golden hamster BHK-21 cells incubated for 72 hrs by MTT assay cytotoxicity against golden hamster BHK-21 cells incubated for 72 hrs by MTT assay	[PMID: 32845145]
BHK-21	CC₅₀	> 100 μM Compound: M 5255	Cytotoxicity against hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay	[PMID: 19482481]
BHK-21	CC₅₀	> 100 μM Compound: M 5255	Cytotoxicity against mock-infected BHK21 cells after 48 to 96 hrs by MTT assay Cytotoxicity against mock-infected BHK21 cells after 48 to 96 hrs by MTT assay	[PMID: 25082514]
BHK-21	EC₅₀	0.04 μM Compound: Mycophenolic acid	Inhibition of West Nile virus VLP replicon in BHK21 cell line Inhibition of West Nile virus VLP replicon in BHK21 cell line	[PMID: 16539402]
BHK-21	EC₅₀	1.4 μM Compound: Mycophenolic acid	Inhibition of West Nile viral Rluc-Neo-Rep in BHK21 cell line Inhibition of West Nile viral Rluc-Neo-Rep in BHK21 cell line	[PMID: 16539402]
BHK-21	EC₅₀	> 100 μM Compound: M 5255	Antiviral activity against Reovirus-1 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay Antiviral activity against Reovirus-1 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay	[PMID: 19482481]
BHK-21	EC₅₀	> 100 μM Compound: M 5255	Antiviral activity against Yellow fever virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay Antiviral activity against Yellow fever virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay	[PMID: 19482481]
BHK-21	EC₅₀	> 100 μM Compound: M 5255	Antiviral activity against Reovirus type-1 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Reovirus type-1 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 25082514]
BHK-21	EC₅₀	> 100 μM Compound: M 5255	Antiviral activity against Yellow fever virus infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Yellow fever virus infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 25082514]
BHK-21	EC₅₀	> 100 μM Compound: M5255	Antiviral activity against Reo-1 virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Reo-1 virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 26443549]
BHK-21	EC₅₀	> 100 μM Compound: M5255	Antiviral activity against YFV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against YFV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 26443549]
CCRF-CEM	IC₅₀	0.34 μM Compound: MPA	In vitro secondary T-cell (CEM) proliferation assay In vitro secondary T-cell (CEM) proliferation assay	[PMID: 12014950]
CCRF-CEM	IC₅₀	0.39 μM Compound: MPA	Inhibitory activity against human T-lymphoblast CEM cell line using T cell proliferation assay Inhibitory activity against human T-lymphoblast CEM cell line using T cell proliferation assay	[PMID: 12127522]
CCRF-CEM	IC₅₀	0.39 μM Compound: MPA	The human T-lymphoblastCEM cell (ATCC) proliferation inhibitory activity was determined The human T-lymphoblastCEM cell (ATCC) proliferation inhibitory activity was determined	[PMID: 12270168]
CCRF-CEM	IC₅₀	0.39 μM Compound: MPA	Inhibitory concentration against human T-lymphoblast CEM cell line (ATCC) by CEM proliferation assay. Inhibitory concentration against human T-lymphoblast CEM cell line (ATCC) by CEM proliferation assay.	[PMID: 12270177]
CCRF-CEM	IC₅₀	0.39 μM Compound: MPA	Inhibitory activity against CEM cell proliferation Inhibitory activity against CEM cell proliferation	[PMID: 12565968]
CCRF-CEM	IC₅₀	0.39 μM Compound: MPA	Inhibitory activity against proliferation of CEM cell line Inhibitory activity against proliferation of CEM cell line	[PMID: 12565969]
CCRF-CEM	IC₅₀	0.54 μM Compound: MPA	Inhibition of CEM cell proliferation Inhibition of CEM cell proliferation	[PMID: 17585753]
CCRF-CEM	IC₅₀	0.9 μM Compound: 1	Cytotoxic activity against HIV uninfected T4 lymphocytes (CEM cell line) Cytotoxic activity against HIV uninfected T4 lymphocytes (CEM cell line)	10.1016/0960-894X(95)00130-L
CCRF-CEM	IC₅₀	340 nM Compound: MPA	Inhibition of CEM (human leukemia) cell proliferation. Inhibition of CEM (human leukemia) cell proliferation.	[PMID: 14505670]
CCRF-CEM	IC₅₀	> 156 μM Compound: 1, MPA	Antiproliferative activity against human CCRF-CEM cells after 48 hrs by MTT assay Antiproliferative activity against human CCRF-CEM cells after 48 hrs by MTT assay	[PMID: 22621840]
DU-145	IC₅₀	2.94 μM Compound: MPA	Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30223117]
FaDu	IC₅₀	6.72 μM Compound: MPA; 1	Cytotoxicity against human FaDu cells assessed as growth inhibition measured by SRB assay Cytotoxicity against human FaDu cells assessed as growth inhibition measured by SRB assay	[PMID: 34044119]
HL-60	IC₅₀	9.76 μM Compound: 1, MPA	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 22621840]
HT-29	IC₅₀	0.4 μM Compound: Mycophenolic acid	Inhibitory activity of compound against HT-29 human colon adenocarcinoma cell line Inhibitory activity of compound against HT-29 human colon adenocarcinoma cell line	[PMID: 8568826]
HT-29	IC₅₀	0.9 μM Compound: 1	In vitro antitumor activity against HT-29 human colon adenocarcinoma cells In vitro antitumor activity against HT-29 human colon adenocarcinoma cells	10.1016/0960-894X(95)00130-L
HT-29	IC₅₀	6.48 μM Compound: MPA; 1	Cytotoxicity against human HT-29 cells assessed as growth inhibition measured by SRB assay Cytotoxicity against human HT-29 cells assessed as growth inhibition measured by SRB assay	[PMID: 34044119]
HUVEC	IC₅₀	99.2 nM Compound: MPA	Antiproliferative activity against HUVEC as measured by [3H]thymidine incorporation Antiproliferative activity against HUVEC as measured by [3H]thymidine incorporation	[PMID: 16640327]
HepG2	IC₅₀	1 μM Compound: 92125597	HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells	[PMID: 22586124]
HepG2	IC₅₀	> 100 μM Compound: 92125597	HARVARD: Cytotoxicity in HepG2 cell line HARVARD: Cytotoxicity in HepG2 cell line	[PMID: 22586124]
Hepatocyte	EC₅₀	5.9 μM Compound: 1; MPA	Toxicity in human hepatocytes assessed by dehydrogenase activity measured after 48 hrs by CCK-8 assay Toxicity in human hepatocytes assessed by dehydrogenase activity measured after 48 hrs by CCK-8 assay	[PMID: 34055230]
Huh-7	CC₅₀	> 100 μM Compound: 1, MPA	Cytotoxicity against human Huh7.5 cells after 96 hrs by MTT assay Cytotoxicity against human Huh7.5 cells after 96 hrs by MTT assay	[PMID: 23999140]
Huh-7	IC₅₀	4.16 μM Compound: 1, MPA	Antiviral activity against HCV expressing pFL-J6/JFH/JC1 infected in human Huh7.5 cells assessed as inhibition of viral RNA synthesis after 96 hrs by one-step RT-PCR analysis Antiviral activity against HCV expressing pFL-J6/JFH/JC1 infected in human Huh7.5 cells assessed as inhibition of viral RNA synthesis after 96 hrs by one-step RT-PCR analysis	[PMID: 23999140]
Jurkat	EC₅₀	0.3 μM Compound: 1; MPA	Immunosuppression-mediated antiproliferative activity against human Jurkat T cells assessed as inhibition of cell growth incubated for 48 hrs by VPD450 staining based flow cytometry Immunosuppression-mediated antiproliferative activity against human Jurkat T cells assessed as inhibition of cell growth incubated for 48 hrs by VPD450 staining based flow cytometry	[PMID: 32007665]
Jurkat	EC₅₀	9.45 μM Compound: 1, MPA, Mycophenolic acid	Antiproliferative activity against human Jurkat cells assessed as incorporation of [3H]thymidine after 18 hrs by scintillation counting analysis Antiproliferative activity against human Jurkat cells assessed as incorporation of [3H]thymidine after 18 hrs by scintillation counting analysis	[PMID: 24121309]
Jurkat	IC₅₀	0.193 μM Compound: 1, MPA	Antiproliferative activity against human Jurkat cells after 48 hrs by MTT assay Antiproliferative activity against human Jurkat cells after 48 hrs by MTT assay	[PMID: 22621840]
Jurkat	IC₅₀	128 nM Compound: MPA	Antiproliferative activity against Jurkat T cells as measured by [3H]thymidine incorporation Antiproliferative activity against Jurkat T cells as measured by [3H]thymidine incorporation	[PMID: 16640327]
Jurkat	IC₅₀	28.21 μM Compound: 1, MPA, Mycophenolic acid	Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay	[PMID: 24121309]
Jurkat	IC₅₀	60.6 μM Compound: 1; MPA	Immunosuppression-mediated cytotoxicity against human Jurkat T cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Immunosuppression-mediated cytotoxicity against human Jurkat T cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32007665]
K562	IC₅₀	0.08 μM Compound: Mycophenolic acid (MPA)	Inhibitory activity against growth of human erythroleukemia K652 cells Inhibitory activity against growth of human erythroleukemia K652 cells	[PMID: 9484510]
K562	IC₅₀	0.19 μM Compound: 1, MPA	Cytotoxicity against human K562 cells after 72 hrs by trypan blue exclusion assay Cytotoxicity against human K562 cells after 72 hrs by trypan blue exclusion assay	[PMID: 20934342]
K562	IC₅₀	7.7 μM Compound: MPA	Antiproliferative activity against human K562 cells after 72 hrs Antiproliferative activity against human K562 cells after 72 hrs	[PMID: 17958343]
K562	IC₅₀	7.7 μM Compound: MPA	Antiproliferative activity against human K562 cells after 72 hrs by MTS assay Antiproliferative activity against human K562 cells after 72 hrs by MTS assay	[PMID: 18809333]
K562	IC₅₀	7.7 μM Compound: MPA	Antiproliferative activity against human K562 cells after 72 hrs by MTS assay Antiproliferative activity against human K562 cells after 72 hrs by MTS assay	[PMID: 21324702]
K562	IC₅₀	7.7 μM Compound: MPA, mycophenolic acid	Antiproliferative activity against human K562 cells after 72 hrs by MTS assay Antiproliferative activity against human K562 cells after 72 hrs by MTS assay	[PMID: 18038969]
L1210	IC₅₀	2.18 μM Compound: 1, MPA	Antiproliferative activity against mouse L1210 cells after 48 hrs by MTT assay Antiproliferative activity against mouse L1210 cells after 48 hrs by MTT assay	[PMID: 22621840]
L1210	IC₅₀	< 0.2 μM Compound: 1	In vitro antitumor activity against L1210 murine lymphocytic leukemia cells In vitro antitumor activity against L1210 murine lymphocytic leukemia cells	10.1016/0960-894X(95)00130-L
L1210	IC₅₀	< 0.2 μM Compound: Mycophenolic acid	Inhibitory activity of compound against L1210 leukemia cells in tissue culture Inhibitory activity of compound against L1210 leukemia cells in tissue culture	[PMID: 8568826]
LLC-MK2	CC₅₀	3.44 μM Compound: 61	Cytotoxicity against Rhesus macaque LLC-MK2 cells incubated for 72 hrs by MTT assay Cytotoxicity against Rhesus macaque LLC-MK2 cells incubated for 72 hrs by MTT assay	[PMID: 32845145]
MCF7	IC₅₀	0.5 μM Compound: 1	In vitro antitumor activity against MCF-7 human breast adenocarcinoma cells In vitro antitumor activity against MCF-7 human breast adenocarcinoma cells	10.1016/0960-894X(95)00130-L
MDA-MB-231	IC₅₀	4.38 μM Compound: MPA	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30223117]
MDA-MB-231	IC₅₀	7.83 μM Compound: MPA; 1	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition measured by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition measured by SRB assay	[PMID: 34044119]
MIN6	EC₅₀	0.6 μM Compound: 1; MPA	Toxicity in mouse MIN6 cells assessed by dehydrogenase activity measured after 48 hrs by CCK-8 assay Toxicity in mouse MIN6 cells assessed by dehydrogenase activity measured after 48 hrs by CCK-8 assay	[PMID: 34055230]
MOLT-4	IC₅₀	0.075 μM Compound: 1, MPA	Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay	[PMID: 22621840]
MT4	CC₅₀	0.2 μM Compound: M 5255	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 19482481]
MT4	CC₅₀	0.2 μM Compound: M 5255	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 20359898]
MT4	CC₅₀	0.2 μM Compound: M 5255	Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay	[PMID: 25082514]
MT4	CC₅₀	0.2 μM Compound: M5255	Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay	[PMID: 26443549]
PBMC	EC₅₀	0.0301 μM Compound: 1; MPA	Immunosuppression-mediated antiproliferative activity against anti-CD3/anti-CD28-stimulated human PBMC cells assessed as inhibition of cell growth incubated for 72 hrs by VPD450 staining based flow cytometry Immunosuppression-mediated antiproliferative activity against anti-CD3/anti-CD28-stimulated human PBMC cells assessed as inhibition of cell growth incubated for 72 hrs by VPD450 staining based flow cytometry	[PMID: 32007665]
PBMC	EC₅₀	uM μM Compound: 1, MPA, Mycophenolic acid	Antiproliferative activity against human PBMC assessed as incorporation of [3H]thymidine after 18 hrs by scintillation counting analysis Antiproliferative activity against human PBMC assessed as incorporation of [3H]thymidine after 18 hrs by scintillation counting analysis	[PMID: 24121309]
PBMC	IC₅₀	0.044 μM Compound: 1, MPA, Mycophenolic acid	Cytotoxicity against human PBMC after 72 hrs by MTT assay Cytotoxicity against human PBMC after 72 hrs by MTT assay	[PMID: 24121309]
PBMC	IC₅₀	0.13 μM Compound: MPA	Inhibition of T cell proliferation in PBMC cells Inhibition of T cell proliferation in PBMC cells	[PMID: 17585753]
PBMC	IC₅₀	0.14 μM Compound: 1; MPA	Immunosuppression-mediated cytotoxicity against anti-CD3/anti-CD28-stimulated human PBMC cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Immunosuppression-mediated cytotoxicity against anti-CD3/anti-CD28-stimulated human PBMC cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32007665]
PBMC	IC₅₀	0.18 μM Compound: Mycophenolic acid	Immunosuppressive activity in anti-CD3/anti-CD28-induced human PBMC after 96 hrs by flow cytometry Immunosuppressive activity in anti-CD3/anti-CD28-induced human PBMC after 96 hrs by flow cytometry	[PMID: 24963543]
PBMC	IC₅₀	1.28 μM Compound: 1, MPA	Antiproliferative activity against activated-human PBMC after 96 hrs by MTT assay Antiproliferative activity against activated-human PBMC after 96 hrs by MTT assay	[PMID: 22621840]
PBMC	IC₅₀	> 100 μM Compound: Mycophenolic acid	Cytotoxicity against human PBMC after 96 hrs by flow cytometry Cytotoxicity against human PBMC after 96 hrs by flow cytometry	[PMID: 24963543]
PSN1	IC₅₀	0.7 μM Compound: 1	In vitro antitumor activity against PSN-1 human pancreatic carcinoma cells In vitro antitumor activity against PSN-1 human pancreatic carcinoma cells	10.1016/0960-894X(95)00130-L
SH-SY5Y	IC₅₀	0.56 μM Compound: MPA; 1	Cytotoxicity against human SH-SY5Y cells assessed as growth inhibition measured by SRB assay Cytotoxicity against human SH-SY5Y cells assessed as growth inhibition measured by SRB assay	[PMID: 34044119]
T-cell	IC₅₀	0.28 μM Compound: MPA	Immunosuppressive activity in in mouse T-cells assessed as inhibition of concanavalin A-induced proliferation Immunosuppressive activity in in mouse T-cells assessed as inhibition of concanavalin A-induced proliferation	[PMID: 22172700]
T-cell	IC₅₀	0.32 μM Compound: 4, MPA	Immunosuppressive activity in C57BL/6 mouse T lymphocytes assessed as inhibition of cell proliferation after 72 hrs by MTT assay Immunosuppressive activity in C57BL/6 mouse T lymphocytes assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 22464133]
U-87MG ATCC	IC₅₀	10.69 μM Compound: MPA	Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30223117]
VSMC	IC₅₀	1 μM Compound: MPA, mycophenolic acid	Antiproliferative activity against PDGF-induced rat aortic VSMC by colorimetric assay Antiproliferative activity against PDGF-induced rat aortic VSMC by colorimetric assay	[PMID: 18400498]
Vero	CC₅₀	18.7 μM Compound: Mycophenolic acid	Cytotoxicity activity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay Cytotoxicity activity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay	[PMID: 32786878]
Vero	CC₅₀	30 μM Compound: 138; MAP	Cytotoxicity against African green monkey Vero cells by neutral red dye uptake assay Cytotoxicity against African green monkey Vero cells by neutral red dye uptake assay	[PMID: 28689975]
Vero	CC₅₀	624.34 μM Compound: 1, MPA	Cytotoxicity against african green monkey Vero cells after 96 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 96 hrs by MTT assay	[PMID: 23999140]
Vero	CC₅₀	>= 12.5 μM Compound: MA	Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by crystal violet staining Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by crystal violet staining	[PMID: 22047799]
Vero	CC₅₀	>= 12.5 μM Compound: Mycophenolic acid	Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay	[PMID: 22513121]
Vero	CC₅₀	>= 13 μM Compound: M 5255	Cytotoxicity against african green monkey Vero 76 cells by crystal violet staining Cytotoxicity against african green monkey Vero 76 cells by crystal violet staining	[PMID: 19482481]
Vero	CC₅₀	>= 13 μM Compound: M 5255	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 20359898]
Vero	EC₅₀	0.04 μM Compound: Mycophenolic acid	Inhibition of Rluc-FL-WNV replicon in Vero cells Inhibition of Rluc-FL-WNV replicon in Vero cells	[PMID: 16539402]
Vero	EC₅₀	0.08 μM Compound: Mycophenolic acid	Inhibition of West Nile viral Rluc-Neo-Rep in Vero cells Inhibition of West Nile viral Rluc-Neo-Rep in Vero cells	[PMID: 16539402]
Vero	EC₅₀	0.4 μM Compound: Mycophenolic acid	Antiviral activity against para influenza 3 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against para influenza 3 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
Vero	EC₅₀	0.6 μM Compound: M 5255	Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	0.6 μM Compound: M 5255	Antiviral activity against Respiratory syncytial virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 5 days by plaque reduction assay Antiviral activity against Respiratory syncytial virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 5 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	0.8 μM Compound: MPA	Antiviral activity against Para-influenza-3 virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis Antiviral activity against Para-influenza-3 virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis	[PMID: 27979594]
Vero	EC₅₀	1.4 μM Compound: Mycophenolic acid	Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
Vero	EC₅₀	1.5 μM Compound: M5255	Antiviral activity against Vaccinia virus infected in African green monkey Vero 76 cells after 3 days by plaque reduction assay Antiviral activity against Vaccinia virus infected in African green monkey Vero 76 cells after 3 days by plaque reduction assay	[PMID: 25913116]
Vero	EC₅₀	1.5 μM Compound: MA	Antiviral activity against Vaccinia virus Lister Elstree infected in african green monkey Vero 76 cells assessed as reduction of virus-induced plaque formation after 3 days using crystal violet staining Antiviral activity against Vaccinia virus Lister Elstree infected in african green monkey Vero 76 cells assessed as reduction of virus-induced plaque formation after 3 days using crystal violet staining	[PMID: 22047799]
Vero	EC₅₀	1.5 μM Compound: Mycophenolic acid	Antiviral activity against Human Vaccinia virus ATCC VR-1549 infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation after 3 days by crystal violet staining Antiviral activity against Human Vaccinia virus ATCC VR-1549 infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation after 3 days by crystal violet staining	[PMID: 26119992]
Vero	EC₅₀	1.8 μM Compound: M5255	Antiviral activity against Vaccinia virus infected African green monkey Vero 76 cells assessed as reduction in plaque number treated after viral infection measured after 3 days by plaque reduction assay Antiviral activity against Vaccinia virus infected African green monkey Vero 76 cells assessed as reduction in plaque number treated after viral infection measured after 3 days by plaque reduction assay	10.1007/s00044-012-0342-1
Vero	EC₅₀	1.8 μM Compound: MPA	Antiviral activity against Reovirus-1 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis Antiviral activity against Reovirus-1 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis	[PMID: 27979594]
Vero	EC₅₀	1.8 μM Compound: Mycophenolic acid	Antiviral activity against Reovirus 1 infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against Reovirus 1 infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
Vero	EC₅₀	2 μM Compound: M 5255	Antiviral activity against Vaccinia Virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay Antiviral activity against Vaccinia Virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	2.3 μM Compound: Mycophenolic acid	Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
Vero	EC₅₀	20 μM Compound: MPA	Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis	[PMID: 27979594]
Vero	EC₅₀	20 μM Compound: Mycophenolic acid	Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
Vero	EC₅₀	4 μM Compound: MPA	Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis	[PMID: 27979594]
Vero	EC₅₀	4 μM Compound: MPA	Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis	[PMID: 27979594]
Vero	EC₅₀	5.7 μM Compound: MPA, Mycophenolic acid	Antiviral activity against Dengue virus 2 NGC infected in african green monkey Vero cells after 3 days by immunofluorescence assay Antiviral activity against Dengue virus 2 NGC infected in african green monkey Vero cells after 3 days by immunofluorescence assay	[PMID: 17360676]
Vero	EC₅₀	> 100 μM Compound: M 5255	Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	> 100 μM Compound: M 5255	Antiviral activity against HSV1 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay Antiviral activity against HSV1 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	> 100 μM Compound: M 5255	Antiviral activity against Poliovirus type 1 Sabin strain infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay Antiviral activity against Poliovirus type 1 Sabin strain infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	> 100 μM Compound: Mycophenolic acid	Antiviral activity against Coxsackie B4 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against Coxsackie B4 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
Vero	EC₅₀	> 13 μM Compound: M 5255	Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	> 13 μM Compound: M 5255	Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	> 13 μM Compound: M 5255	Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	> 250 μM Compound: MPA	Antiviral activity against Coxsackie virus B4 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis Antiviral activity against Coxsackie virus B4 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis	[PMID: 27979594]
Vero	IC₅₀	10.15 μM Compound: 1, MPA	Antiviral activity against Coxsackie B3 virus Nancy in african green monkey Vero cells assessed as inhibition virus-induced cytopathic effect after 48 hrs Antiviral activity against Coxsackie B3 virus Nancy in african green monkey Vero cells assessed as inhibition virus-induced cytopathic effect after 48 hrs	[PMID: 23999140]
Vero	IC₅₀	69.36 μM Compound: 1, MPA	Antiviral activity against Coxsackie B6 virus Schmitt in african green monkey Vero cells assessed as inhibition virus-induced cytopathic effect after 48 hrs Antiviral activity against Coxsackie B6 virus Schmitt in african green monkey Vero cells assessed as inhibition virus-induced cytopathic effect after 48 hrs	[PMID: 23999140]
Vero 76	CC₅₀	19 μM Compound: M5255	Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method	[PMID: 25913116]
Vero 76	CC₅₀	20 μM Compound: M 5255	Cytotoxicity against mock-infected african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay Cytotoxicity against mock-infected african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay	[PMID: 25082514]
Vero 76	CC₅₀	20 μM Compound: M5255	Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method	[PMID: 26443549]
Vero 76	CC₅₀	9 μM Compound: M5255	Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay	[PMID: 29028528]
Vero 76	CC₅₀	> 100 μM Compound: Mycophenolic acid	Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining	[PMID: 26119992]
Vero 76	CC₅₀	> 12.5 μM Compound: MA	Cytotoxicity against mock-infected african green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against mock-infected african green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay	[PMID: 27161176]
Vero 76	EC₅₀	0.6 μM Compound: M 5255	Antiviral activity against Respiratory syncytial virus A2 infected in Vero-76 cells after 5 days by plaque reduction assay Antiviral activity against Respiratory syncytial virus A2 infected in Vero-76 cells after 5 days by plaque reduction assay	[PMID: 19482481]
Vero 76	EC₅₀	0.6 μM Compound: M5255	Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay	[PMID: 26443549]
Vero 76	EC₅₀	1.5 μM Compound: Mycophenolic acid	Antiviral activity against Vaccinia virus Elstree-Lister ATCC VR-1549 infected in african green monkey Vero-76 cells assessed as reduction in viral plaque after 3 days by crystal violet staining Antiviral activity against Vaccinia virus Elstree-Lister ATCC VR-1549 infected in african green monkey Vero-76 cells assessed as reduction in viral plaque after 3 days by crystal violet staining	[PMID: 22513121]
Vero 76	EC₅₀	1.8 μM Compound: M 5255	Antiviral activity against Vaccinia virus infected African green monkey Vero76 cells assessed as reduction of virus-induced plaque reduction after 3 days by MTT assay Antiviral activity against Vaccinia virus infected African green monkey Vero76 cells assessed as reduction of virus-induced plaque reduction after 3 days by MTT assay	10.1007/s00044-010-9513-0
Vero 76	EC₅₀	> 100 μM Compound: M5255	Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay	[PMID: 26443549]
Vero 76	EC₅₀	> 100 μM Compound: M5255	Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay	[PMID: 26443549]
Vero 76	EC₅₀	> 13 μM Compound: M 5255	Antiviral activity against Coxsackie virus type B2 virus infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay Antiviral activity against Coxsackie virus type B2 virus infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay	[PMID: 19482481]
Vero 76	EC₅₀	> 13 μM Compound: M 5255	Antiviral activity against HSV1 infected in Vero-76 cells after 3 days by plaque reduction assay Antiviral activity against HSV1 infected in Vero-76 cells after 3 days by plaque reduction assay	[PMID: 19482481]

体外研究
(In Vitro)

Mycophenolic acid 对多种 RNA 病毒具有抗病毒作用，包括流感、登革热病毒、寨卡病毒、轮状病毒、CCHFV 和汉坦病毒^[1]。
IMPDH 是病毒中的限速酶鸟苷核苷酸的从头合成^[2]。
Mycophenolic acid (0.01-1 μM；72 小时) 对内皮细胞和成纤维细胞表现出优先的抗增殖活性.内皮细胞是对 Mycophenolic acid 处理最敏感的细胞，其抗有丝分裂作用的 IC₅₀ <500 nM^[2]。
成纤维细胞也容易受到 Mycophenolic acid-诱导细胞周期抑制，但与内皮细胞相比表现出更高的 IC₅₀ (<1 μM)。两种人类肿瘤细胞系 A549 非小细胞肺癌细胞和 PC3 前列腺癌细胞表现出中等敏感性，IC₅₀ >1 μM。U87 胶质母细胞瘤细胞对高达 1 μM 的 MPA 处理具有抗性^[2]。
Mycophenolic acid (0.05-2 μM；18 小时) 对 HDAC2 和 MYC 表现出剂量依赖性下调，而上调 NDRG1^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:	Primary isolated human dermal microvascular endothelial cells (HDMVEC) , fibroblasts, U87 glioblastoma cells, PC3 prostate cancer cells, A549 non-small cell lung cancer cells
Concentration:	0.01, 0.1, 1 μM
Incubation Time:	72 hours
Result:	Exhibited preferential antiproliferative activity against HDMVEC and fibroblasts. Whereas U87 glioblastoma cells were resistant to treatment, A549 non-small cell lung cancer and PC3 prostate cancer cells showed intermediate sensitivity.

Western Blot Analysis^[2]

Cell Line:	HDMVEC
Concentration:	0, 0.05, 0.1, 0.5, 1, and 2 μM
Incubation Time:	18 hours
Result:	Showed a dose-dependent regulation of HDAC2, MYC, and NDRG1.

体内研究
(In Vivo)

Mycophenolic acid 通过调节肿瘤微环境发挥抗肿瘤作用，在 BALB/c 裸鼠体内显著抑制 U87 肿瘤生长^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Athymic 8-week-old, 20 g BALB/c nu/nu mice bearing Mycophenolic acid-resistant human U87 tumor model^[2]
Dosage:	120 mg/kg MMF (the morpholinoethyl ester prodrug of Mycophenolic acid)
Administration:	Oral gavage; b.i.d.
Result:	MMF (the morpholinoethyl ester prodrug of Mycophenolic acid) significantly inhibited tumor growth (∼70% after day 14 after tumor implantation) in MMF-treated versus control mice. Microvessel density (CD31 staining) and pericyte coverage determined by α-smooth muscle actin staining were markedly reduced in MMF-treated versus control tumors (44% and 78%, respectively).

Clinical Trial

分子量

320.34

Formula

C₁₇H₂₀O₆

CAS 号

24280-93-1

性状

固体

颜色

White to off-white

中文名称

霉酚酸

结构分类

Ketones, Aldehydes, Acids

初始来源

微生物

内源性代谢物

several species of Penicillium

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性数据

细胞实验：

DMSO 中的溶解度 : ≥ 100 mg/mL (312.17 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

H₂O 中的溶解度 : < 0.1 mg/mL (insoluble)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.1217 mL	15.6084 mL	31.2168 mL
5 mM	0.6243 mL	3.1217 mL	6.2434 mL
10 mM	0.3122 mL	1.5608 mL	3.1217 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.80 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.80 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (7.80 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： Corn Oil
Solubility: 33.33 mg/mL (104.05 mM); 悬浊液; 超声助溶 (<60°C)

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.94%

选择批次：

Data Sheet (651 KB) SDS (537 KB)

COA (285 KB) HNMR (266 KB) LCMS (94 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Stephen R Welch, et al. Screening and Identification of Lujo Virus Inhibitors Using a Recombinant Reporter Virus Platform. Viruses. 2021 Jun 28;13(7):1255. [Content Brief]

[2]. Sophie Domhan, et al. Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid. Mol Cancer Ther. 2008 Jun;7(6):1656-68. [Content Brief]

Mycophenolic acid 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.1217 mL	15.6084 mL	31.2168 mL	78.0421 mL
	5 mM	0.6243 mL	3.1217 mL	6.2434 mL	15.6084 mL
	10 mM	0.3122 mL	1.5608 mL	3.1217 mL	7.8042 mL
	15 mM	0.2081 mL	1.0406 mL	2.0811 mL	5.2028 mL
	20 mM	0.1561 mL	0.7804 mL	1.5608 mL	3.9021 mL
	25 mM	0.1249 mL	0.6243 mL	1.2487 mL	3.1217 mL
	30 mM	0.1041 mL	0.5203 mL	1.0406 mL	2.6014 mL
	40 mM	0.0780 mL	0.3902 mL	0.7804 mL	1.9511 mL
	50 mM	0.0624 mL	0.3122 mL	0.6243 mL	1.5608 mL
	60 mM	0.0520 mL	0.2601 mL	0.5203 mL	1.3007 mL
	80 mM	0.0390 mL	0.1951 mL	0.3902 mL	0.9755 mL
	100 mM	0.0312 mL	0.1561 mL	0.3122 mL	0.7804 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Mycophenolic acid (Synonyms: 霉酚酸; Mycophenolate)

Customer Review

Other Forms of Mycophenolic acid:

MCE 顾客使用本产品发表的 11 篇科研文献

Mycophenolic acid 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Antibiotic 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Mycophenolic acid 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Mycophenolic acid (Synonyms: 霉酚酸; Mycophenolate)

Customer Review

Other Forms of Mycophenolic acid:

Mycophenolic acid 相关抗体

MCE 顾客使用本产品发表的 11 篇科研文献

Mycophenolic acid 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Antibiotic 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

Mycophenolic acid 相关抗体:

摩尔计算器

稀释计算器

Mycophenolic acid 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z